Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pravachol judicial windfall

Executive Summary

Bristol-Myers Squibb netted an estimated $13.4 mil. from the four-day delay of generic pravastatin market entry, based on average Pravachol sales during the first quarter of $3.35 mil. per day in the U.S. Bristol's compound patent expired April 20, and FDA delays approval of Teva's 10 mg, 20 mg and 40 mg pravastatin ANDAs until April 24. The delay resulted from an April 20 D.C. Circuit Court of Appeals ruling enjoining FDA from approving pravastatin ANDAs until the court had time to review a motion for injunctive relief from Apotex. Bristol was not a party to the case. Ranbaxy, which holds 180-day exclusivity rights for the 80 mg dose, still awaits FDA approval[Editor's note: In-depth coverage of Pravachol legal proceedings appeared in 1"The Pink Sheet" DAILYApril 25. To read the article and sign up for a free trial, visit our website, 2www.ThePinkSheetDAILY.com.]...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel